Previous 10 | Next 10 |
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies withupcoming pay dates. For further details see: Dividend Champion, Contender, And...
Danaher Corporation ( NYSE:DHR ) had several weeks of downward pressure on the price. The stock appears to have consolidated in the range between $262 and $297. Currently, the stock is trading at $276. The PEG ratio is 1.28, and the company is still rated low on value and growth...
Danaher Corporation (DHR) Q1 2022 Earnings Conference Call April 21, 2022 08:00 ET Company Participants John Bedford - Vice President, Investor Relations Rainer Blair - President and Chief Executive Officer Matt McGrew - Executive Vice President and Chief Financial Officer Conference Call Par...
Life sciences company, Danaher (NYSE:DHR), is trading flat in the pre-market Thursday even after reporting better than expected financials for 1Q 2022 as its topline growth continued to show signs of a slowdown amid waning COVID-19 benefit. The quarterly revenue for the company climbed ~12% Y...
Danaher press release (NYSE:DHR): Q1 Non-GAAP EPS of $2.76 beats by $0.10. Revenue of $7.69B (+12.1% Y/Y) beats by $160M. For FY2022, the company continues to expect non-GAAP base business core revenue growth will be in the high-single digit percent range. For further details see: Danah...
Danaher Reports First Quarter 2022 Results PR Newswire WASHINGTON , April 21, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the first quarter 2022. For the quarter ended April 1, 2022 , net earnin...
Danaher (NYSE:DHR) is scheduled to announce Q1 earnings results on Thursday, April 21st, before market open. The consensus EPS Estimate is $2.66 (+5.6% Y/Y) and the consensus Revenue Estimate is $7.53B (+9.8% Y/Y). Over the last 2 years, DHR has beaten EPS estimates 100% of the time and has b...
As Danaher (DHR) is set to kick off the earnings season of the makers of Life Sciences & Diagnostic Tools on Thursday, Bank of America analysts led by Derik de Bruin issued cautious views on the subsector, citing macro and geopolitical headwinds. The earnings season for the group com...
This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q4-2021 13F filings the consensus holdings were updated, 7 stocks were removed and 7 added from the unive...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration PR Newswire BREA, Calif. , July 25, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the Dx...
2024-07-23 20:30:03 ET Goldman Sachs analyst issues NEUTRAL recommendation for DHR on July 23, 2024 06:19PM ET. The previous analyst recommendation was Neutral. DHR was trading at $264.18 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...